Medshine Discovery Inc.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Fujian Akeylink Biotechnology Co., Ltd.

Luoxin Pharmaceutical (shanghai) Co., Ltd.

Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.

Jiangsu Aosaikang Pharmaceutical Co., Ltd.

Qilu Pharmaceutical Co., Ltd.

Genfleet Therapeutics (shanghai) Inc.

Hubei Bio-pharmaceutical Industrial Technological Institute Inc.

Humanwell Healthcare (group) Co., Ltd.

Harbin Zhenbao Pharmaceutical Co., Ltd.

Nanjing Sanhome Pharmaceutical Co., Ltd.

Cstone Pharmaceuticals

Guangdong Zhongsheng Pharmaceutical Co., Ltd

Wuxi Fortune Pharmaceutical Co., Ltd

Charles Z Ding

Shuhui Chen

Lihong Hu

Jian Li

Guoping Hu

Fei Sun

Jianyu Lu

Yong Wang

Xile Liu

Weidong Li

Zhaobing Xu

Zhe Cai

Zhigang Huang

Huijun He

Fei Wang

Cheng Li

Xiquan Zhang

Shenyi Shi

Jiaqiang Dong

Tie-Lin Wang

Xiongbin Xu

Lifang Wu

Xiaobing Yan

Yingchun Liu

Baoping Zhao

Haiwen Wan

Yanbin Hu

Wei Luo

Wei Huang

Zheng Wang

Cong Wang

Hui Liu

Hongjiang Xu

Ling Yang

Lingyun Wu

Kun Peng Wang

Yong Xu

Lie Li

Chao Ding

Wen Jiang

Lu Huang

Cailin Wang

Xuehai Wang

Ronghua Tu

Jie Shen

Lun Lu

Hailiang Chen

Wenjie Sun

Yaxian Cai

Yang YuE

Ruibin Lin

Linxia Xiao

Hailong Yang

Shiqi Han

Xiangyu Fu

Jinhua Du

Jimeng Wang

Biao Deng

Ting Wang

Hao Wu

Chengde Wu

Lu Zhang

Dan Li

Yuquan Wei

Wenyuan Qian

Fei Liu

Rui Zhao

Jun Zhao

Xu Zeng

Lele Zhao

Weiwei Mao

Ning Zhao

Bin Shi

Boyu Hu

Ting Yao

Xiawei Wei

Zongbin Li

Wei Pan

Zhibo Zhang

Lili Fan

Qingqing Lu

Dongdong Tang

Xiu Jiang

Minliang Xiao

Kun Wang

Jinsheng Xie

Bingjie Ren

Zhigang Chi

Xingxun Zhu

Lianghu Gu

Jinping Li

Yaling Zhou

Zhijuan Chen

Wenqian Yang

Shuwen Duan

Yanxiao Su

Lili Zhou

Provided is an isochroman compound represented by formula (I), or a pharmaceutically acceptable salt thereof, which is used as an aldo-keto reductase (AKR1C3) inhibitor for the treatment of liver cancer.

Isochroman compound

A class of KRAS G12C mutant protein inhibitors, specifically disclosing the compound shown in formula (I), and an isomer and a pharmaceutically acceptable salt thereof.

Seven-membered heterocyclic derivative acting as KRAS G12C mutant protein inhibitor

Provided is a preparation method for an oxazepine compound, and specifically disclosed are a preparation method for a compound of formula (I) and an intermediate of same.

Preparation method for oxazepine compound

Disclosed are a new class of antibacterial aminoglycoside derivatives, pharmaceutical compositions containing such compounds, and application thereof in the preparation of drugs for treating diseases related to bacterial infections. Specifically disclosed are a compound represented by formula (II), pharmaceutically acceptable salts thereof, and isomers thereof.

Antibacterial aminoglycoside derivatives

Disclosed are a group of 5-(4-pyridyloxy)pyrazole compounds serving as a TGF-βR1 kinase inhibitor, and applications of same in preparing a TGF-βR1 kinase inhibitor medicament. Specifically disclosed are the compounds as represented by formula (I), a pharmaceutically acceptable salt or an isomer thereof.

5-(4-pyridyloxy)pyrazole compounds serving as TGF-βR1 kinase inhibitor

An application of a compound represented by formula (I) and pharmaceutically acceptable salts thereof in preparation of a drug for treating pneumonia.

Application of monocyclic β-lactam compound in pharmacy

Provided is an indole compound. In particular, disclosed are a compound represented by formula (II) or an isomer or pharmaceutically acceptable salt thereof and a use of the same as an estrogen receptor antagonist in preparing a drug for treating estrogen receptor-positive breast cancer.

Estrogen receptor antagonist

Disclosed are a pyrimidinyl group-containing tricyclic compound and applications thereof in preparing a cancer-treating medicament. Specifically disclosed are a compound as represented by formula (I), a pharmaceutically acceptable salt of same, or an isomer thereof.

Pyrimidinyl group-containing tricyclic compound serving as c-Met inhibitor

The present invention discloses a crystal form of a hepatitis B surface antigen inhibitor and a preparation method therefor, and also comprises the use of the crystal form in preparing the hepatitis B surface antigen inhibitor.

Crystal form of hepatitis B surface antigen inhibitor

Provided are a salt form of an estrogen receptor down-regulator, a crystalline form thereof, and a preparation method therefor

Salt form of estrogen receptor downregulator, crystalline form thereof, and preparation method therefor

The present invention relates to a structurally novel TLR8 (Toll-like receptor 8) agonist and, in particular, to a compound thereof of formula (I), a pharmaceutically acceptable salt and an isomer thereof.

TLR8 agonist

A TLR8 (Toll-like receptor 8) agonist, a compound of the structure shown in formula (I), an isomer thereof, or a pharmaceutically acceptable salt thereof.

Disclosed are a class of macrocyclic derivatives, a preparation method therefor, a pharmaceutical composition containing the derivatives, and the use thereof as therapeutic agents, particularly as XIa factor inhibitors and in the preparation of a drug for treating and preventing thromboembolisms and other diseases. Particularly disclosed are compounds shown by formula (I), an isomer thereof and a pharmaceutically acceptable salt thereof.

Macrocyclic derivatives acting as XIa factor inhibitor

Disclosed is a crystal form of a hepatitis B surface antigen inhibitor and a preparation method, and an application of the crystal form in the preparation of the hepatitis B surface antigen inhibitor.

Crystal form of hepatitis B surface antigen inhibitor and application thereof

Disclosed is a class of compounds containing arylsultam, and specifically disclosed are a compound represented by formula (II), and a pharmaceutically acceptable salt or an isomer thereof.

Compounds containing benzosultam

Growing community of inventors

Shanghai, China

Charles Z Ding